HUM vs. CNC, ELV, MOH, BDX, GSK, BSX, MCK, HCA, TAK, and EW
Should you be buying Humana stock or one of its competitors? The main competitors of Humana include Centene (CNC), Elevance Health (ELV), Molina Healthcare (MOH), Becton, Dickinson and (BDX), GSK (GSK), Boston Scientific (BSX), McKesson (MCK), HCA Healthcare (HCA), Takeda Pharmaceutical (TAK), and Edwards Lifesciences (EW). These companies are all part of the "medical" sector.
Humana vs.
Centene (NYSE:CNC) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends.
Centene has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.
In the previous week, Humana had 4 more articles in the media than Centene. MarketBeat recorded 12 mentions for Humana and 8 mentions for Centene. Centene's average media sentiment score of 0.50 beat Humana's score of 0.04 indicating that Centene is being referred to more favorably in the media.
Humana has a net margin of 3.26% compared to Centene's net margin of 1.01%. Humana's return on equity of 21.04% beat Centene's return on equity.
93.3% of Centene shares are owned by institutional investors. Comparatively, 93.4% of Humana shares are owned by institutional investors. 0.3% of Centene shares are owned by insiders. Comparatively, 0.3% of Humana shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Humana has lower revenue, but higher earnings than Centene. Humana is trading at a lower price-to-earnings ratio than Centene, indicating that it is currently the more affordable of the two stocks.
Centene presently has a consensus target price of $91.11, suggesting a potential upside of 37.09%. Humana has a consensus target price of $599.72, suggesting a potential upside of 15.16%. Given Centene's higher possible upside, analysts plainly believe Centene is more favorable than Humana.
Centene received 141 more outperform votes than Humana when rated by MarketBeat users. Likewise, 73.72% of users gave Centene an outperform vote while only 64.69% of users gave Humana an outperform vote.
Summary
Humana beats Centene on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HUM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools